1 / 34

Drug Interactions

Drug Interactions. New Zealand College of Pharmacists. Purpose of Presentation. This presentation supplements the course materials. Risk Factors for Drug Interactions. High Risk Patients Elderly, young, very sick, multiple disease Multiple drug therapy Renal, liver impairment

francis-vaughan
Download Presentation

Drug Interactions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Drug Interactions New Zealand College of Pharmacists

  2. Purpose of Presentation • This presentation supplements the course materials

  3. Risk Factors for Drug Interactions • High Risk Patients • Elderly, young, very sick, multiple disease • Multiple drug therapy • Renal, liver impairment • High Risk Drugs • Narrow therapeutic index drugs • Recognised enzyme inhibitors or inducers

  4. Lithium Digoxin Carbamazepine Cyclosporin Phenytoin Phenobarbitone Theophylline (Aminophylline) Warfarin Some drugs with a low therapeutic index

  5. Pharmacodynamic Drug Interactions One drug causes a change in patient response to another drug without altering that drug’s pharmacokinetics • Eg increase toxicity of digoxin caused by diuretic induced hypokalaemia • Additive effects of alcohol and benzodiazepines • Beta-blocker given with beta-agonist

  6. Pharmaceutical Interactions Interactions that occur prior to systemic administration. • For example incompatibility between two drugs mixed in an IV fluid. These interactions can be physical (e.g. with a visible precipitate) or chemical with no visible sign of a problem

  7. PharmacokineticDrug Interactions • One drug alters the rate or extent of absorption, distribution, metabolism or excretion of another drug. • A change in blood concentration causes a change in the drug’s effect.

  8. Altered Absorption (Availability) • Change in gastrointestinal pH • Ketoconazole needs acidic conditions in gut • Drug binding in GI tract • E.g. tetracycline and calcium • Change in gastrointestinal flora • Antibiotics with OCs • Change in gastrointestinal motility • Metoclopramide and digoxin • Malabsorption caused by other drugs • Orlistat (Xenical) and fat soluble vitamins

  9. CYP450 Nomenclature Family CYP2D6 Individual Gene Sub-Family

  10. CYP 450 SystemDefinitions • Substrate:Drug is metabolised by the enzyme system • Inducer:Drug that will increase the synthesis of CYP450 enzymes • InhibitorDrug that will decrease the metabolism of a substrate

  11. Enzyme Induction 1 • Leads to production of more enzyme, usually after 3-4 days of exposure to inducer • Most CYPs are inducible but not CYP2D6 • Time course of interaction depends on half-life of inducer.

  12. Enzyme Induction 2 • Rifampicin has short half-life and induction apparent with 24 hours • Phenobarbitone has longer half life so time to complete induction takes longer

  13. Enzyme InducersExamples • Rifampicin • Phenobarbitone • Carbamazepine • Cigarette smoke

  14. Enzyme Inhibition • Often rapid, reversible and relatively short acting.E.g. erythromycin and cyclosporinNB erythromycin is a substrate and an inhibitor ofCYP 3A4 • May be prolonged due to long half- life of drug.E.g. amiodarone and S-WarfarinNB amiodarone is an inhibitor of CYP2C9 but not a substrate for this CYP

  15. Enzyme characteristics% drugs metabolised by enzyme • 3A4 60% • 2D6 25% • 1A2 15% • 2C9 Small no. but significant interactions • 2C19 Small no. but significant interactions • 2E1 ?

  16. EXCRETION Drug A increases or reduces the excretion (usually renal) of Drug B. Blood levels of B fall below or rise above normal therapeutic range. Becomes either ineffective or toxic.

  17. Excretion Interactions • Mechanisms of urinary excretion: • - Simple filtration • - Active secretion • Mechanisms for active secretion • - Acids • - Bases

  18. Excretion interactions Active secretion mechanisms have limited capacity. e.g. One acid drug may saturate the acid drug active secretion mechanism. Another acid drug will then be secreted less efficiently

  19. Excretion InteractionLithium + Thiazides • Probable mechanism: • Thiazides cause diuresis and initial sodium loss. • Compensatory sodium retention in proximal • tubules. • Proximal tubules do not distinguish sodium • from lithium. • Lithium also retained and accumulates.

  20. Excretion InteractionChange in renal blood flow • Methotrexate and NSAIDs NSAIDS can decrease renal blood flow by inhibition of renal prostaglandins. Reduced clearance of MTX and active (toxic) metabolite

  21. Protein BindingDrug Displacement Plasma Tissue Drug B Drug A protein bound Drug A free Drug A free Drugs A and B both bind to the same plasma protein

  22. Protein Binding Interactions • Importance has been over emphasised • Protein binding is a dynamic state • Increased availability of free drug displaced from plasma proteins ……….. But compensatory mechanisms maintain free drug concentration • Only important in interpretation of total drug concentrations e.g. phenytoin/VPA

  23. Barbiturates (3A) Carbamazepine(2C19, 3A) Phenytoin (3A) Rifampicin(2C19, 2C9, 3A) St Johns Wort (3A) Ethanol (2E1) Troglitazone (3A) Tobacco (1A2) Omeprazole (1A2) Nevirapine (3A) Some enzyme Inducers

  24. Where are these enzymes ? • Most cells • Predominantly in endoplasmic reticulum of hepatocytes • Also present in gut wall • Kidney lungs and brain • Liver is main site of drug metabolism

  25. Significance of Gut CYPs • CYP3A4 most important. Quite high concentrations in mucosa of small intestine • Activity is 20-300 fold less than in whole liver • Quantitatively significant if oral dose is small or rate of absorption very slow.

  26. Enzyme characteristicsGenetic Polymorphism • CY2D6PM- 5-10% Caucasians, <1% Asians(Also “super-fast metabolisers) • CYP2C9PM 1-3% Caucasians • CY2C19PM- 3-5% Caucasians, 15-20% Asians

  27. Enzyme CharacteristicsInterindividual Enzyme Content • CYP3A4 x 5 • CYP2D6 > 50 • CYP1A2 x 20 • CYP2C9 x 5 • CYP2C19 ? • CYP2E1 x 12

  28. Free drug Liver Conjugate Bile Free drug Bacteria Conjugate Gut Interactions via Enterohepatic Circulation (EHC)

  29. Case 1SSRI/TCA • What is the mechanism of the pharmacokinetic interaction ? • What possible pharmacodynamic interactions are there ? • What would be the most hazardous combination ? • What would be the safest combination ? • How would the interaction be managed ?

  30. Case 2SSRI/Tramadol • What CYP enzyme is involved in the metabolism of both these drugs ? • What possible interactions are there ? • Where can you find information on this interaction ? • Are there any case reports in the literature ? • How would you find these case reports ?

  31. Case 3 Patient taking timolol eye drops (for more than six months).Complains of slow heart rate and dizziness shortly after taking cimetidine tablets which he had bought OTC. • What is the mechanism of this interaction ? • How could the interaction be managed ?

  32. ACE/Diuretics/NSAIDS • Prescriber Update July 2002 • Diuretics (hypovolaemia) • ACE Inhibition of RAA system therefore less constriction of efferent arteioles from glomerulus • NSAIDS/COX-2 inhibition of renal prostaglandins, therefore less dilataion of afferent arterioles.

More Related